TET2 and gastric cancer: The results showed that pPLK-CircR_101996, pPLK-TET2, and pLV-miR-143 all markedly reduced the tumor size of GC (Figure 5A, B), while the pPLK-CircR_101996 and pPLK-TET2 could both inhibit abdominal metastasis (Figure 5C).